Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2025)

Sunshine Biopharma's Restructuring Costs history spans 5 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Restructuring Costs rose 67.48% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $3.9 million, up 26.26%, while the annual FY2025 figure was $3.9 million, 24.26% up from the prior year.
  • Restructuring Costs reached $1.5 million in Q4 2025 per SBFM's latest filing, up from $614661.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $1.5 million in Q4 2025 to a low of $530334.0 in Q3 2024.
  • Average Restructuring Costs over 3 years is $818994.2, with a median of $763451.0 recorded in 2023.
  • Peak YoY movement for Restructuring Costs: fell 2.55% in 2024, then surged 67.48% in 2025.
  • A 3-year view of Restructuring Costs shows it stood at $720297.0 in 2023, then rose by 25.79% to $906056.0 in 2024, then soared by 67.48% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Restructuring Costs are $1.5 million (Q4 2025), $614661.0 (Q3 2025), and $806605.0 (Q2 2025).